HOME >> BIOLOGY >> NEWS
Chiron reports on discovery of novel men B vaccine candidates based on whole genome sequencing of Neisseria meningitidis by TIGR

Emeryville, CA, March 9, 2000 -- Chiron Corporation (Nasdaq: CHIR) today announced that its research team located in Siena, together with collaborators at The Institute for Genomics Research (TIGR) in Rockville, Maryland, and the University of Oxford, have determined the complete genome sequence for Neisseria meningitidis, the bacterium primarily responsible for meningococcal disease. Chiron also reported that it has used this detailed information on the microorganism's genetic structure to identify novel vaccine candidates against meningococcal B disease. This research, reported in the March 10, 2000 issue of Science, demonstrates the important role genomics can play in the development of commercial products.

"Conventional research approaches to develop effective vaccines against different strains of group B meningococcus have failed," said Rino Rappuoli, Ph.D., co-author of the Science papers and Chiron's vice president of vaccine research. "A genomics-based approach is a completely novel paradigm and allowed the discovery of many vaccine candidates which will be used for developing new methods of protection."

Dr. Rappuoli added, "Through this research we also have a better understanding of the disease process. Using these insights, we are creating a vaccine capable of protecting against the broad diversity of invasive strains of this virulent microorganism. This progress could only have been achieved by the collaboration of three groups, each with unique expertise, in sequencing the genome (TIGR), in the biology and pathogenesis of the bacterium (Oxford), and in vaccine development (Chiron)".

Traditional approaches to vaccine development against meningococcal B disease have proved problematic in eliciting a strong immune response against multiple strains of the disease. Using information gained from sequencing the entire genome, researchers were able to identify new surface proteins. These newly discovered proteins behave differen
'"/>

Contact: Amy Giller
a.giller@noonanrusso.com
415-677-4455 x206
Noonan/Russo Communications
8-Mar-2000


Page: 1 2

Related biology news :

1. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
2. Chiron Discovers Significant Hepatitis C Binding Mechanism; Data Indicates CD81 Protein May Be A Virus Receptor
3. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
4. Scientists question reports of massive ant supercolonies in California and Europe
5. Survey reports fall in stem cell transplants for breast cancer
6. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
7. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
8. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
9. Measles on the rise as vaccinations fall in the UK, Science study reports
10. WCS biologist George Schaller reports surprising increase in Tibets wildlife
11. Clinical study reports findings of combination therapy with DOXIL

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: